Mr. Ryan Rhodes serves as Chief Executive Officer of EDAP TMS S.A. since May 01, 2023 and serves as Director since August 23, 2023. He served as Chief Executive Officer and President of Venus Concept Inc....

리더십 팀

이름	위치	테뉴어	보상	소유권
Marc Oczachowski	Executive Chairman	6.9yrs	데이터 없음	데이터 없음
Ryan Rhodes	CEO & Director	1.1yrs	데이터 없음	데이터 없음
Ken Mobeck	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Carre Emmanuel	Chief Operating Officer	no data	데이터 없음	데이터 없음
Francois Dietsch	Chief Accounting Officer	less than a year	데이터 없음	데이터 없음
Blandine Confort	Head of Legal Affairs & Investor Relations and Secretary	no data	데이터 없음	데이터 없음
Frederic Pech	President of EDAP TMS France	1.1yrs	데이터 없음	데이터 없음
Jean-Francois Bachelard	President & Chief Executive Officer of Edaptechnomed Co. Ltd.	15.4yrs	데이터 없음	데이터 없음

1.1yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: EDAP 의 관리팀은 경험 (평균 재직 기간 1.1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Marc Oczachowski	Executive Chairman	6.9yrs	데이터 없음	데이터 없음
Ryan Rhodes	CEO & Director	less than a year	데이터 없음	데이터 없음
Lance Willsey	Independent Director	less than a year	데이터 없음	데이터 없음
Pierre Beysson	Independent Director	21.8yrs	데이터 없음	데이터 없음
Marie Meynadier	Independent Director	4yrs	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: EDAP 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

EDAP TMS 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

EDAP TMS S.A. Appoints Francois Dietsch as Global Chief Accounting Officer

Less than half of directors are independent

EDAP TMS S.A. Announces Board Changes

EDAP TMS S.A. Announces Board Changes

Insufficient new directors

EDAP TMS S.A., Annual General Meeting, Jun 30, 2023

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 35%, revenue upgraded

EDAP TMS S.A. to Report Q1, 2024 Results on May 16, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024

EDAP TMS SA Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis

Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?

EDAP TMS S.A. Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One Hifu Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A. Appoints Francois Dietsch as Global Chief Accounting Officer

Less than half of directors are independent

EDAP TMS S.A. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

EDAP TMS S.A. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

EDAP TMS S.A. Announces Board Changes

New major risk - Revenue and earnings growth

EDAP TMS S.A. to Report Q2, 2023 Results on Aug 24, 2023

Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)

Insufficient new directors

EDAP TMS S.A., Annual General Meeting, Jun 30, 2023

Consensus EPS estimates fall by 199%

Price target increased by 9.1% to US$15.00

First quarter 2023 earnings released: €0.20 loss per share (vs €0.011 profit in 1Q 2022)

EDAP TMS S.A. to Report Q1, 2023 Results on May 17, 2023

Price target increased by 12% to US$14.50

Full year 2022 earnings released: €0.085 loss per share (vs €0.022 profit in FY 2021)

Consensus EPS estimates increase by 36%

EDAP TMS SA Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound for the Treatment of Rectal Endometriosis

Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?

Now 20% undervalued

EDAP TMS S.A. Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis

EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals

Consensus EPS estimates have been upgraded

Third quarter 2022 earnings released: EPS: €0 (vs €0.03 loss in 3Q 2021)

Now -35% undervalued

EDAP TMS S.A. to Report Q3, 2022 Results on Nov 16, 2022

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS stock falls 7% aftermarket on proposed ADS offering

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

EDAP's Focal One Revenue Is Set To Accelerate

EDAP TMS S.A. to Report Q2, 2022 Results on Aug 24, 2022

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

EDAP TMS S.A., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. to Report Q1, 2022 Results on May 17, 2022

EDAP TMS S.A. to Showcase Its Focal One® Platform At the Annual Meeting of the American Urological Association

Price target decreased to US$12.00

Consensus EPS estimates have been downgraded.

Full year 2021 earnings: EPS and revenues miss analyst expectations

EDAP TMS S.A. to Report Q4, 2021 Results on Mar 30, 2022

EDAP Announces Publication of Positive Pre-clinical Results Using Intraoperative HIFU Ablation of the Pancreas in the Journal Cancers

Acceleration At EDAP

EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt

The Consensus EPS Estimates For EDAP TMS S.A. (NASDAQ:EDAP) Just Fell A Lot

Third quarter 2021 earnings released: €0.03 loss per share (vs €0.034 loss in 3Q 2020)

Price target decreased to US$11.50

EDAP's HIFU Progress Is Obscured By The Pandemic, But It's Real

Mega Elektroniikka Oy agreed to acquire a 25% stake in Technomed Medical Systems S.A from EDAP TMS S.A. (NasdaqGM : EDAP).

Second quarter 2021 earnings released: €0.013 loss per share (vs €0.006 loss in 2Q 2020)